The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more heated.

Novo launched a rival bid to acquire American obesity biotech firm Metsera last week, superseding an offer for the firm from ...

There are strict rules about what drug companies can say in TV or print ads. But a new study shows there's a lot more wiggle ...

People taking popular new weight-loss drugs such as Wegovy and Zepbound often celebrate the number of pounds they shed and ...

Semaglutide appears to safeguard the heart even when patients lose little weight. In a massive international trial, heart attack and stroke risk dropped by 20% regardless of BMI. The benefit seems ...

A new Gallup poll indicates that the obesity rate among U.S. adults has declined over the past three years as the number of ...

Regardless of how much weight you lose, GLP-1 drugs like Wegovy and Ozempic could decrease major adverse cardiovascular ...

Ozempic may be used off-label for weight loss. However, some people may experience weight gain while using Ozempic or after ...

GLP-1 drugs, originally developed for diabetes and obesity, may also curb addictive behaviors by acting on reward circuits in ...

Ozempic has taken TikTok by storm. It’s hailed as a miracle weight loss drug that helps you shed the pounds without even really trying. Sound too good to be true? Well, it could be. There’s lots of ...

Bariatric weight-loss surgery can help patients lose five times more weight than popular medications like Ozempic, expanding ...

Microdosing GLP-1 weight loss drugs like semaglutide is trendy, with supporters touting benefits such as lower costs and potentially fewer side effects. But some doctors are skeptical, calling it ...